Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. The Company\'s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncology\'s lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, the Company is advancing a number of pipeline programs, including anti-signal regulatory protein (SIRP) antibodies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/25/19 | $50,000,000 | Series B |
3x5 Partners Lightchain  RiverVest Venture Partners Roche Venture Fund | undisclosed |
| 04/28/21 | $105,000,000 | Series C |
3x5 Partners Adage Capital Management Avego Bioscience Capital Broadfin Holdings Cowen Healthcare Investments Eventide Asset Management FMB Research Lightchain Point72 Asset Management RiverVest Venture Partners Roche Venture Fund | undisclosed |
